Breaking News

New treatment for Non Alcoholic Fatty Liver Disease

By Chioma OBINNA
Respite last week came on the way of patients suffering from Non Alcoholic Fatty Liver Disease as a new research has clinically proven that Tocotrienols can be use to achieve a complete remission of Non Alcoholic Fatty Liver Disease, NAFLD, which hitherto had no effective treatment.

Non Alcoholic Fatty Liver Disease is a group of diseases arising from the excessive accummulation of triglycerides and other fats in liver cells. Risk factors are thought to include obesity, diabetes, hyperlipidemia, sedentary lifestyle, etc. The global prevalence is currently put at 30 per cent of the adult population or over 500 million people. The prevalence is over 90 per cent among obese diabetics.

Medical community

The news came as a welcome relief to the medical community as NAFLD,according to medical experts,  if not controlled, could lead to hepatitis, liver cirrhosis, liver failure or liver cancer. Statistics show that in the next decade, NAFLD will be the major cause of liver transplant. It is already known to be a major cause of abnormal liver function.

The discovery was made by Hovid Bhd, a Malaysian based international pharmaceutical company. Tocovid SupraBio, a brand of tocotrienols, now established as an effective liver-protective, is an innovative product from Hovid Bhd,  and is exclusively marketed in Nigeria by Phamatex Nigeria Limited.

Assistant General Manager, Phamatex Nigeria Limited, Pharmacist Sunday Onyeke,  made the disclosure during the 2011 Annual Dinner and Award Night of the Association of General and Private Medical Practitioners of Nigeria (AGPMPN), in Lagos recently.


Comments expressed here do not reflect the opinions of vanguard newspapers or any employee thereof.